Navigation Links
Wistar receives $4.7 million to develop drug against Epstein-Barr virus-related cancers
Date:12/15/2011

The Wistar Institute today announced that it has signed a funding agreement with the Wellcome Trust, a United Kingdom-based charity, to support the development of a new drug to treat cancers associated with Epstein-Barr virus (EBV). The Seeding Drug Discovery Award of up to $4.7 million will support on-going translational research in the laboratory of Wistar Professor Paul M. Lieberman, Ph.D. If successful, the new therapeutic could be the first to treat EBV-related cancer by attacking the virus as it remains dormant in a patient's cells.

The project is a three-year, multi-stage effort where funding is based on the achievement of defined research milestones, outlined by Lieberman and Troy Messick, Ph.D., a staff scientist in the Lieberman laboratory and co-leader on the project.

"On behalf of The Wistar Institute, I would like to thank the Wellcome Trust for seeing the potential for this project to save countless lives across the globe," said Russel E. Kaufman, M.D., CEO and president of The Wistar Institute. "This effort reflects translational research at its finest by combining a visionary charitable foundation, a promising line of research, and a solid plan for transforming basic science into practical medicine."

Epstein-Barr Virus (EBV) is classified by the World Health Organization as a Class I carcinogen, and it is estimated to cause a small but significant portion of all human cancers. The virus may persist in the human body for decades and cause infected cells to become cancerous. It is estimated that EBV causes nearly 400,000 cases of cancer each year, including Burkitt's lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, gastric carcinoma and certain oral and throat cancers.

According to Lieberman, EBNA1, a protein produced by EBV, is a prime target for therapeutic intervention. The protein acts as the master switch that regulates viral gene activity and guides the ability of EBV to remain dormant in the body.

"EBNA1 is expressed consistently in all EBV-related cancer and is essential for the virus to reproduce," said Lieberman. "Knocking out EBNA1, therefore, could likely eliminate latent Epstein-Barr virus and control the growth of EBV-associated cancer."

Lieberman heads Wistar's Center for Chemical Biology and Translational Medicine, a team of researchers whose mission is to develop promising basic research findings into new therapeutics to fight disease, particularly cancer.

To develop an anti-EBV drug, the researchers began a complex screening process to find a small molecule that could chemically bind to EBNA1 and inhibit its ability to function. They began with a library of 600,000 molecular compounds, eventually narrowing the pool down through a series of tests to a handful of leading candidate molecules that have the most potential to serve as the basis of new anti-EBV drug.

With funds from the Wellcome Trust, the Wistar researchers will further optimize their candidate small molecule inhibitors, with the aim of developing at least one chemical compound into a viable drug candidate. This drug candidate could then be used in clinical trials designed to determine its safety and effectiveness for humans.

"This is an investment in drug discovery, enabling a small team of experts to do the type of translational research typically seen in large drug companies," said Messick. "If successful with the translational research funded by the Wellcome Trust, the program will be in a position to attract a commercial partner to undertake further clinical development."
'/>"/>

Contact: Greg Lester
glester@wistar.org
215-898-3943
The Wistar Institute
Source:Eurekalert  

Related medicine news :

1. Wistar researchers: Direct proof of how T cells stay in standby mode
2. Wistar researchers follow a path to a potential therapy for NF2, a rare tumor disorder
3. Wistar researchers discover new class of objects encoded within the genome
4. Wistar scientists explain the persistence of melanoma through dynamic stemness
5. Northwestern receives $10 million gift for life sciences graduates
6. RI Hospital receives $1.5 million grant to study treatments for body dysmorphic disorder
7. Thomas Jefferson University receives Science Centers QED Award for pancreatic cancer research
8. BMC resident receives American Society for Clinical Pathology awards
9. R. Michael Scott, M.D., receives the Franc D. Ingraham Distinguished Service Award
10. Kessler Foundation receives grant to study cognitive reserve in traumatic brain injury
11. Kessler Foundation receives grants to study health disparities in people with disabilities
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Wistar receives $4.7 million to develop drug against Epstein-Barr virus-related cancers
(Date:1/24/2017)... ... January 24, 2017 , ... The Behavioral ... with an Award of Distinction, recognizing the organization as a top behavioral service ... in the areas of clinical quality, staff satisfaction, and qualifications and consumer satisfaction. ...
(Date:1/24/2017)... , ... January 24, 2017 , ... World Patent Marketing, ... its website invention store . , Retro Patents was co-founded by Craig ... that gives users access to millions of songs, acquired Soundwave from Craig in 2016. ...
(Date:1/24/2017)... ... January 24, 2017 , ... ... United States Environmental Protection Agency (EPA) in its new recommendations of standards ... Innovation Institute has announced. , Cradle to Cradle Certified is recommended at ...
(Date:1/24/2017)... Plains, N.J. (PRWEB) , ... January 24, 2017 , ... ... helping patients for nearly six decades. She joins Dr. Robert V. Scalera, Jr., ... addition to our practice,” said Dr. Scalera, Jr., a general dentist and director of ...
(Date:1/24/2017)... ... January 24, 2017 , ... A fifth-year speaker at the 2017 ... will return to present about the state of the Affordable Care Act (ACA) with ... this year – will be hosted at Disney’s Grand Californian Hotel & Spa from ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... , Jan. 24, 2017 The Society ... and the Physician-Patient Alliance for Health & Safety ( ... focused on promoting safety and optimized outcomes for patients ... Gross MD, President of SONORIA and Michael Wong ... serve as advisors to their respective organization,s Boards. ...
(Date:1/24/2017)... , January 24, 2017 www.Financialbuzz.com ... growing industries in the United States ... in 2016. In addition, Proposition 64, the California Cannabis Legalization ... 42.87% against on November 8, 2016. This outcome means that ... use and to grow a certain amount of cannabis for ...
(Date:1/24/2017)... 24, 2017 Mezzion has filed a suit ... court alleging that Dr. Reddy,s committed fraud relating to ... Drug Administration (FDA) cGMP practices, and misrepresenting its compliance ... represented to Mezzion that it was compliant with FDA ... The suit also states that Dr. Reddy,s misconduct was ...
Breaking Medicine Technology: